Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Dankner

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|March 26, 2023
Gender Disparities in Academic Outcomes Among Graduates of a Canadian MD-PhD ProgramJoan Miguel Romero, Mark Sorin, Matthew Dankner, et al.
Breast Cancer Research : BCR|August 18, 2025
Cold-inducible RNA-binding protein is associated with subtype-specific breast cancer patient outcomesMatthew Dankner, Veronique Ouellet, Jakob Lafon, et al.
Cancers|January 26, 2024
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant CancersSuzanne Kazandjian, Emmanuelle Rousselle, Matthew Dankner, et al.
Anti-Cancer Drugs|June 8, 2018
DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapyCynthia Bernier, Ahmed Soliman, Michel Gravel, et al.
Journal of Neuro-Oncology|December 20, 2024
Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic diseaseJie Wei Zhu, Megan Shum, Maleeha A Qazi, et al.
The American Journal of Pathology|June 17, 2019
CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient PrognosisMatthew Dankner, Véronique Ouellet, Laudine Communal, et al.
Current Oncology (Toronto, Ont.)|January 24, 2025
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single CentreAnna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, et al.
Current Oncology (Toronto, Ont.)|November 26, 2025
Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-AnalysisMatthew Dankner, Laurie-Rose Dubé, Mark Sorin, et al.
Heliyon|May 3, 2024
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysissDavid J H Bian, Anna-Maria Lazaratos, Sarah M Maritan, et al.
Cell Reports|April 6, 2022
Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapyShivshankari Rajkumar, Diana Berry, Kayla A Heney, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|March 26, 2023
Gender Disparities in Academic Outcomes Among Graduates of a Canadian MD-PhD ProgramJoan Miguel Romero, Mark Sorin, Matthew Dankner, et al.
Breast Cancer Research : BCR|August 18, 2025
Cold-inducible RNA-binding protein is associated with subtype-specific breast cancer patient outcomesMatthew Dankner, Veronique Ouellet, Jakob Lafon, et al.
Cancers|January 26, 2024
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant CancersSuzanne Kazandjian, Emmanuelle Rousselle, Matthew Dankner, et al.
Anti-Cancer Drugs|June 8, 2018
DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapyCynthia Bernier, Ahmed Soliman, Michel Gravel, et al.
Journal of Neuro-Oncology|December 20, 2024
Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic diseaseJie Wei Zhu, Megan Shum, Maleeha A Qazi, et al.
The American Journal of Pathology|June 17, 2019
CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient PrognosisMatthew Dankner, Véronique Ouellet, Laudine Communal, et al.
Current Oncology (Toronto, Ont.)|January 24, 2025
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single CentreAnna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, et al.
Current Oncology (Toronto, Ont.)|November 26, 2025
Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-AnalysisMatthew Dankner, Laurie-Rose Dubé, Mark Sorin, et al.
Heliyon|May 3, 2024
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysissDavid J H Bian, Anna-Maria Lazaratos, Sarah M Maritan, et al.
Cell Reports|April 6, 2022
Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapyShivshankari Rajkumar, Diana Berry, Kayla A Heney, et al.
Pageof 4